A Guide to Using Slow-Release Oral Morphine in Opioid Agonist Therapy

Speaker: Marie-ève Goyer, Institut universitaire sur les dépendances, Canada

We Demand OST Now – How Successful PWUD-Led Campaign Fast-Tracked Initiation of OST Services in Kwale County, Kenya

Speaker: Ahmed Mohamed Said, Africa Network Of People Use Drugs, Kenya

Maintenance on Extended-Release Naltrexone is Associated With Reduced Injection Opioid Use Among Justice-Involved Persons With Opioid Use Disorder

Speaker: Sandra Springer, Yale School Of Medicine, USA

Injection Drug Use Patterns and Changes Associated With HCV Treatment

Speaker: Benjamin Eckhardt, NYU School of Medicine/Bellevue Hospital, USA

Association Between History of Incarceration an Prevalence of Drug Use Across 7 Countries in Europe 2014 to 2018

Speaker: Sara Mazzilli, Scuola Normale Superiore, Pisa, Italy

Injecting Drugs On and Off: Factors Associated With Stopping Injection Drug Use Among Young PWID

Speaker: Pedro Mateu-Gelabert, CUNY – School Of Public Health, USA

Prevalence of Injected Drug Use and Access to OAT in People Living in Prison Across 7 Countries in Europe 2014 to 2018

Speaker: Sara Mazzilli, Scuola Normale Superiore, Pisa, Italy

Substance Use Practices Among People who Inject Drugs in Kenya Preparing for Hepatitis C Treatment

Speaker: Lindsey Riback, Albert Einstein College Of Medicine/Montefiore Medical Center, USA

Feasibility and Acceptability of an Overdose Prevention Intervention Delivered by Community Pharmacists for Patients Prescribed Opioids from Chronic Non-Cancer Pain

Speaker: Moussa Konate, Paroles Autour de la Santé, Mali

The Effect of Opioid Analgesics, Benzodiazepines, Gabapentinoids, and Opioid Agonist Treatment On Mortality Risk Among Opioid-Dependent People

Speaker: Chrianna Bharat, NDARC, UNSW Sydney, Australia

Mapping a Global Profile of People who Inject Drugs

Speaker: Louisa Degenhardt, NDARC UNSW, Australia

Risk-Compensation and Loss-To-Follow-Up Among PWID in an HCV Vaccine Trial

Speaker: Nikhet Chowdhury, University Of New Mexico, USA

Adjusting the HCV Comprehension in Colombia: Vulnerable Contexts and the Need to go Beyond Injected Drug Users

Speaker: Levinson Niño, Lanpud, Colombia

A New Model of Care For HCV Elimination in PWUD in The Balearic Islands, Spain

Speaker: Andrea Mochales, ISGlobal, Spain

Bristol and Severn ODN Hepatitis C Outreach: a Flexible Model of Care for Screening

Speaker: Ann Archer, University Hospitals Bristol and Weston, UK

Bridging The Digital Divide & Enhancing Linkage to Hepatitis C Care After Prison Release: The Test Link Call Project

Speaker: Sofia Bartlett, BC Centre for Disease Control, Clinical Prevention Services, Canada

Achieving Micro-Elimination of Hepatitis C in West Kent Change, Grow, Live, the first large, multi-site drug treatment service to do so in England, UK.

Speaker: Jo Brown, Cgl West Kent, UK

The Hep C Drug Treatment Providers Forum HCV Testing Weeks

Speaker: Rebecca John, Turning Point, UK

Use of Modern Screening and Contact Methods in Oat Clinics to Increase HCV Screening and Linkage to Care

Speaker: Kate Johnston, Canadian Addiction Treatment Centres, Canada

Pan-Dorset Hepatitis C Mental Health Engagement Pilot

Speaker: Louise Hansford, Inclusion, UK

Simplified Hepatitis C Testing and Linkage to Care in Addiction Recovery and County Correctional Facilities Model of Care

Speaker: Kathi Scholz, Central Outreach Wellness Center, USA

Peers Power: Increasing the Uptake of HCV Testing and Treatment Amongst People Who Inject Drugs

Speaker: Faizah Hamid, Reachout Centre Trust, Kenya

Effectiveness of Safe Harm Reduction Spaces For Young Persons Who Use Drugs Living With HIV and Viral Hepatitis Co-Infection in Lagos, Nigeria (Aged 15 Yrs – 29 Yrs)

Speaker: James Eghaghe, Equal Health And Rights Access Advocacy Initiative Ehraai, Nigeria

Access Barriers to Diagnosis and Treatment of Hepatitis C For PWID in Pereira (Colombia): The Role of Community Based Organizations

Speaker: Hugo Castro, Ong Temeride, Colombia

More Than Tested, Cured: A Holistic Model of HCV Care Implemented at Syringe Services Programs

Speaker: Mojgan Zare, Atlanta Harm Reduction Coalition, Inc, USA

Belfast Inclusion Health Service – Enhancing Health and Hepatitis Care for People Experiencing Homelessness

Speaker: Bronagh McBrien, Public Health Agency, UK

Keep Your Foot On The Pedal! Kombi Clinic Leads Re-Elimination at Lotus Glen Correctional Centre

Speaker: Mim O’Flynn, Kombi Clinic Ltd, Australia

HIV and HCV Care Continuum Through Testing in the Etet Oeiras/Cascais

Speaker: Ana Marques, Ser+, Portuguese Association For Aids Challenge And Prevention, Portugal

From HCV Diagnosis to Treatment Initiation in Drug Users: Results From a Mobile Outreach Program in Lisbon

Speaker: Claudia Pereira, Ares Do Pinhal, Portugal

Optimising the Opportunity of HCV Testing and Treatment Within a Large Substance Misuse Service

Speaker: Carrie Richardson, The Hepatitis C Trust, UK

The Community Pop-Up Clinic (CPC): a Unique Strategy to Achieve HCV Elimination in The Inner City

Speaker: Brian Conway, Vancouver Infectious Diseases Centre, Canada

A Peer Led Partnership Achieves Whole SMS Service HCV Testing and Treatment

Speaker: Carrie Richardson, The Hepatitis C Trust, UK

Optimizing Clinical Care in The Inner-City Population: Innovative Community HCV-Based Clinic

Speaker: Brian Conway, Vancouver Infectious Diseases Centre, Canada

Hepatitis C Inreach: Opportunistic Inpatient Hepatitis C Identification and Treatment

Speaker: Kim Macbeth, NHS Lothian, UK

“Time To Give It Away” – Peer Led, Same Day Treatment for Hepatitis C: A Pilot Study

Speaker: Julian Surey, Find&Treat, UCLH NHS Trust, UK

A Partnership Approach to Enabling Access to Hepatitis C Treatment Without Visiting The Hospital in a Remote Setting

Speaker: Anngie Everitt, Menzies School Of Health Research, Australia

A Definite Pathway was Successful for HCV Elimination in Caserta Prisons

Speaker: Vincenzo Messina, Uoc Malattie Infettive A.O. S. Anna E S. Sebastiano Caserta, Italy

Outcomes of a Pharmacist-led Care Delivery Model for Patients on Methadone Maintenance Therapy With Chronic Hepatitis C

Speaker: Sara DiTursi, Catholic Health System, USA

Low-Barrier Treatment of Chronic HCV Via Telehealth at a Rural Syringe Exchange Program

Speaker: Sara DeJesus, Berkshire Harm Reduction, USA

Leveraging The Emergency Department as a Public Health Safety Net For Hepatitis C and HIV Services

Speaker: Barbra Cave, University Of Louisville, USA

Detecting and Treating Hepatitis C (HCV) in Addiction Centres in Our Community

Speaker: Sonia Blanco-Sampascual, Hospital universitario Basurto, Spain

Making Hepatitis C Treatment More Accessible: A Test and Treat Mobile Unit in Catalonia

Speaker: Xavier Majó, Programe On Prevention, Care And Control Of Viral Hepatitis (Public Health Agency Of Catalonia), Spain

Adapt The System, Not The Person: Improving the HCV Care Pathways Between the Drug Care Centres and Their Referral Hospitals in Catalonia

Speaker: Xavier Majó, Programe On Prevention, Care And Control Of Viral Hepatitis (Public Health Agency Of Catalonia), Spain

Peers and Medical Staff Testing for Hepatitis C, The Best Match to Reach Drug Users and Make Them Hepatitis Free

Speaker: Juliette Pont, SOS Hépatites Bourgogne Franche-Comté, France

Meeting Clients Wherever They Are At: A Responsive Model of HEP C Care in Toronto, Canada

Speaker: Kate Mason, Toronto Community Hep C Program, Canada

Nurse Practitioner-Led Mobile Health Units Working towards Elimination of Hepatitis C Virus in Rural and Urban South Carolina – A Call to Action

Speaker: Ashley Coleman, Prisma Health, USA

The Importance of a Person-Centred Approach in Achieving Hepatitis C Elimination; Learnings From a Nurse-Led Outreach Hepatitis C Model of Care.

Speaker: Joshua Dawe, Burnet Institute, Australia

A Community-Based Trial of Hepatitis C Treatment at Point of Diagnosis for Marginalized Populations: Preliminary Results From the No One Waits (NOW) Study

Speaker: Meghan Morris, University Of California, San Francisco, USA

A New York City Health Department Collaboration to Improve Hepatitis C Screening and Navigation Services to Underserved Populations

Speaker: Jackilyn Rivera, New York City Dept. Of Health And Mental Hygiene, USA

The HCV Free Hospital, a Simplified Procedure for HCV Screening

Speaker: Vincenzo Messina, Uoc Malattie Infettive A.O. S. Anna E S. Sebastiano Caserta, Italy

Supporting The Development of Effective Monitoring and Evaluation Frameworks in Community Organisation Settings; Learnings From an Australian Hepatitis C Elimination Program

Speaker: Joshua Dawe, Burnet Institute, Australia

Hepatitis C Virus Prevalence From 2010-2015 Among People Experiencing Unstable Housing in a Population – Based Data Linkage Study

Speaker: Sofia Bartlett, BC Centre for Disease Control, Clinical Prevention Services, Canada

Hepatitis C Care Cascade in British Columbia Provincial Correctional Centres Prior to Launch of a Continuous Quality Improvement Project

Speaker: Sofia Bartlett, BC Centre for Disease Control, Clinical Prevention Services, Canada

HCV Prevalence and Risk Behaviours Among People Who Inject Drugs Attending Needle and Syringe Programmes in Lisbon, Portugal

Speaker: Adriana Curado, Gat, Portugal

Prevalence of HCV Infection in Vulnerable Populations: DETECT-C Program a Real Contribution to Hepatitis C Elimination in These Groups in Spain

Speaker: Marinela Mendez, Gilead Science Spain, Spain

One Year of the Drug Consumption Room (DCR) in the City of Lisbon: Preliminary Results of HCV Positive Drug Users and Policy Implications

Speaker: Claudia Pereira, Ares Do Pinhal, Portugal

Hepatitis C Virus Among Patients Visiting a Sexually Transmitted Infections Clinic

Speaker: Michaela Maynard, Brown University, USA

Hepatitis C Virus Prevalence and Outcomes Among Pregnant Women Who Inject Drugs

Speaker: Anthony Martinez, University At Buffalo, USA

Trends in Hepatitis C Prevalence in San Francisco: Progress Toward Elimination

Speaker: Shelley Facente, Facente Consulting, USA

Assessing The Extent of Hepatitis C (HCV) Infection Among Men who Inject Anabolic Androgenic Steroids in The UK: An Urgent Need to Address Uncertainty in Key Parameters to Better Understand the Impact on HCV Elimination.

Speaker: Vivian Hope, PHI, LJMU, UK

Hepatitis C Treatment Among Men Leaving Prison Who Have Histories of Injecting Drug Use in Victoria, Australia

Speaker: Ashleigh Stewart, Burnet Institute, Australia

Hepatitis C Infection Among People Who Use Drugs: A Retrospective Cohort Study Using Administrative Health Records

Speaker: Luca Ceccarelli, University of Pisa, Italy

An Outbreak of Hepatitis C and HIV in Northern Ireland in People who Inject Drugs

Speaker: Sarah Arnold, Public Health Agency, UK

The Road Towards Elimination of Hepatitis C in Oslo: Cross-Sectional Prevalence Studies in 2018 and 2021

Speaker: Eirik Opheim, Agency For Social And Welfare Services, City Of Oslo, Norway, Norway

Modelling of Hepatitis C Elimination in Wales. Is Wales On Track?

Speaker: Brendan Healy, Public Health Wales, UK

HCV Exposure, Chronic Infection and Phylogenetic Linkages in a Community Sample of Young Opioid Users in New York City: Opportunity for HCV Elimination

Speaker: Pedro Mateu-Gelabert, CUNY – School Of Public Health, USA

HCV Genotypes Among Injecting Drug Users Enrolled in Harm Reduction Programs in Tunisia

Speaker: Amin Ghrabi, Florida State University, USA

Evaluating The Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention For People Who Inject Drugs (Epitope) – A Natural Experiment

Speaker: Matt Hickman, Professor in Public Health and Epidemiology, UK

Hepatitis C Treatment Initiation Among People Who Inject Drugs in Australia: Time-to-Event Analysis of a Longitudinal Cohort

Speaker: Phyo Aung, Burnet Institute, Australia 

Increased Uptake of HCV Treatment Associated With Scale-Up of Direct-Acting Antivirals in Community Settings: A National Record-Linkage Study

Speaker: Shanley Smith, Glasgow Caledonian University / Public Health Scotland, UK

Provincial Variability in HCV Testing, Care, and Treatment Across Canada

Speaker: MIa Biondi, York University, Canada

HCV Treatment Among Fentanyl Users: Towards Universal Access to Antiviral Therapy

Speaker: Brian Conway, Vancouver Infectious Diseases Centre, Canada

Identifying Potential Modes of Transmission of Hepatitis C in People Who Inject Drugs Versus the General Population in Punjab, India

Speaker: Roli Tandon, Clinton Health Access Initiative, India

Increasing Linkage to HCV Care Following Trauma-Informed Rehabilitation: An Education and Quality Improvement Project Among Women

Speaker: Agustina Crespi, Viral Hepatitis Care Network, Canada

Awareness of HCV Infection Status Among People Who Inject Drugs in a Setting of Universal Direct-Acting Antiviral Therapy: The Ethos Engage Study

Speaker: Heather Valerio, The Kirby Institute, Australia

Estimating the HCV Treatment Reach in People Who Inject Drugs (PWID) Needed to Meet 2030 WHO Elimination Targets

Speaker: Shiyin Jiao, AbbVie, USA

Micro Elimination of Hepatitis C in Active Drug Users Population Admited for Detoxication in a Unit for Drug Users

Speaker: Davide Cruz, Regional Health Administration Of The Centre (ars Centro, Ip) – Detoxification Unit Of Coimbra (udc), Portugal

Epidemiology of Hepatitis B and Hepatitis C Viruses Among Pregnant Women at Queen Elizabeth Central Hospital (QECH), Malawi

Speaker: Isaac Shawa, University Of Malawi, Malawi

Hepatitis C Elimination Program in Penitentiary Establishments in Central Greece

Speaker: Ioannis Xynotroulas, General Hospital Of Lamia, Greece

Does Combined Needle and Syringe Program and Opioid Agonist Therapy Reduce HIV and Hepatitis C Virus Acquisition Among People Who Inject Drugs in Different Settings?

Speaker: Daniela Van Santen, GGD Amsterdam, Netherlands

Genomic Diversity of HCV Among Intravenous Drug Users in The District of Darjiling, ‘The Queen of Hills’, India

Speaker: Supradip Dutta, National Institute of Cholera and Enteric Diseases, India

Individual and Structural Factors Associated With Recent Hepatitis C Testing in People Who Inject Drugs: Gender-Based Analyses of The Cosinus Cohort

Speaker: Ilhame Anwar, Sesstim Inserm, France

Disparities in Hepatitis C Treatment Uptake Among U.S. Medicaid Enrollees in 2018: Analysis of National Administrative Data

Speaker: Shashi Kapadia, Weill Cornell Medicine, USA

The Effectiveness of Low Dead Space Syringes for Reducing the Risk of Hepatitis C Virus Acquisition Among People Who Inject Drugs – Findings From a National Survey in England, Wales, and Northern Ireland

Speaker: Peter Vickerman, University Of Bristol, UK

Patient Reported Outcomes of Recovery and Quality of Life Post Hepatitis C Treatment

Speaker: Gabriele Vojt, Glasgow Caledonian University, UK

Ongoing Transmission of HCV Infection in Community Recruited People Who Inject Drugs in Athens, Greece (2018-2020)

Speaker: Sotirios Roussos, National and Kapodistrian University of Athens, Greece

Prevalence of Hepatitis Among Opioid Drug Users Receiving Methadone-Assisted Therapy in Southern Highlands Zone (SHL), Tanzania

Speaker: Adela Peter Luswetula, Hjf Medical Research International, Inc Tanzania, Tanzania

Late Presentation of Chronic Hepatitis C in a Swiss Cohort of People on Opioid Agonist Therapy

Speaker: Alberto Moriggia, Ingrado Servizi per le Dipendenze, Lugano, Epatocentro Ticino SA, Lugano, Switzerland

When Health Department Data Don’t Cut it: Strategies to Track an Epidemic

Speaker: Shelley Facente, Facente Consulting, USA

Genomic Variation of HCV Among Idu Subpopulation in The North-Eastern State of Manipur, India

Speaker: Raina Das, ICMR-NICED, India

Mental Disorders and Hepatitis C Prevalence in People on Opioid Agoniste Therapy Followed at The Sammsu Cohort, Switzerland.

Speaker: Erika Castro, Private Practice – HepC Virtual Clinic, Switzerland

The Relationship Between Opioid Agonist Therapy and Hepatitis C Virus Seroprevalence Among People who Inject Drugs in Southern Appalachian Ohio in 2019

Speaker: Daniel Brook, Ohio State University, USA

High Burden of Blood-Borne Viral Infections (HCV, HIV, HBV) and Sexually Transmitted Infections Among People Experiencing Homelessness – First Results From a Pilot Study in Berlin, Germany

Speaker: Christoph Weber, Checkpoint Bln, Germany

Prevalence of Hepatitis B and C, HIV, and Syphilis Among People Who Inject Drugs in Germany – Results of a Pilot Study For a Periodical National Monitoring System

Speaker: Amrei Krings, Robert Koch-institute, Germany

National Direct Acting Antiviral Utilization For Retreatment of Hepatitis C Virus Due to Reinfection or Virological Failure in Australia

Speaker: Joanne Carson, The Kirby Institute, UNSW Sydney, Australia

Reinfection Rate (RR) in People Who Inject Drugs (PWIDs) After Successful HCV Treatment. Data From an Expertized Hepatology Clinic in Northern Greece (Thessaloniki)

Speaker: Effrosyni Tsirogianni, Fourth Department of Internal Medicine, Hippokration General Hospital, Thessaloniki, Greece

Low Hepatitis C Virus Reinfection in People Who Inject Drugs Treated with Direct Acting Antivirals in Kenya

Speaker: Abbe Muller, Boston University Medical Center, USA

Correlates of HCV Reinfection Among Active Drug Users

Speaker: Brian Conway, Vancouver Infectious Diseases Centre, Canada

Reinfections After Hepatitis C Treatment at a Swedish Needle Exchange Program – Follow-Up On The Actionne Study

Speaker: Marianne Alanko Blomé, Department Of Infectious Diseases, Skåne University Hospital, Malmö, Sweden

HCV Reinfection Rate in Drug Users Who Received DAA Through Decentralized HCV Care Provided in Two Harm Reduction Services In Milan, Italy

Speaker: Sara Mazzilli, Scuola Normale Superiore, Pisa, Italy

Exploring the Lived Experience of HCV Reinfection

Speaker: Amy McEwan, Glasgow Caledonian University, UK

Re-Infection Rates of Hepatitis C in Individuals who Achieved Sustained Virologic Response After Treatment With Direct Acting Antiviral Therapy

Speaker: Sophie Starke, Dalhousie University, Canada

HCV Treatment Among Active Inner City Drug Users With Glecaprevir/Pibrentasvir (G/P): The Grand Plan Study

Speaker: Brian Conway, Vancouver Infectious Diseases Centre, Canada

Understanding Unsuccessful Direct-Acting Antiviral Hepatitis C Treatment Among People Living With HIV From The International Collaboration on Hepatitis C Elimination in HIV Cohorts (INCHECH)

Speaker: Brendan Harney, Burnet Institute, Australia

Provider Attitudes Towards Treating HCV in People Living With HIV who are Currently Using Drugs

Speaker: Jack Buyske, Columbia University, USA

Comorbidities, Comedication and Drug-Drug Interactions in Patients With Hepatitis C and Addiction or Drug Abuse Treated With Direct-Acting Antivirals

Speaker: Marinela Mendez, Gilead Science Spain, Spain

Clinical Impact of Drug-Drug Interactions in the Use of Antipsychotics on HCV Patients Treated with Pangenotypic Direct-Acting Antivirals

Speaker: Marinela Mendez, Gilead Science Spain, Spain

Patients’ Reported Experiences With Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in People Who Use Drugs

Speaker: Giaele Moretti, Scuola Superiore Sant’anna, Italy

Epidemiological Approaches to Measure HIV Test Uptake Among People Who Inject Drugs and Evaluate the Response to an HIV Outbreak in Glasgow, Scotland

Speaker: Kirsten Trayner, Glasgow Caledonian University/Public Health Scotland, UK

Effect of Social Distancing Measures During the COVID-19 Pandemic on People Who Inject Drugs in Thessaloniki, Greece

Speaker: Effrosyni Tsirogianni, Fourth Department of Internal Medicine, Hippokration General Hospital, Thessaloniki, Greece

Perceptions of and Willingness to Receive COVID-19 Vaccination Among Unvaccinated People Who Use Drugs: New York City, Spring 2021

Speaker: Ashly Jordan, New York City Department Of Health And Mental Hygiene Bureau Of Alcohol And Drug Use Prevention, Use And Treatment, USA

Coping With COVID in Corrections: A Qualitative Study Among the Recently Incarcerated on Pursing Substance Use Disorder Treatment During the Pandemic

Speaker: Lindsey Riback, Albert Einstein College Of Medicine/Montefiore Medical Center, USA

Effect on HCV Treatment Among People Who Inject Drugs During the COVID-19 Pandemic. Data From a Expertized Hepatology Clinic in Northern Greece (Thessaloniki)

Speaker: Effrosyni Tsirogianni, Fourth Department of Internal Medicine, Hippokration General Hospital, Thessaloniki, Greece

Impact of COVID-19 on Substance Use Disorder Treatment Services and Centers; Qualitative Findings From Healthcare Providers in Kenya

Speaker: Abbe Muller, Boston University Medical Center, USA

Factors Associated With Changes in Illicit Opioid Use During the COVID-19 Pandemic Among Incarcerated People Who Use Drugs in Quebec, Canada

Speaker: Nadine Kronfli, Mcgill University, Canada

Addressing HCV, HIV and Syphilis Rates Among Indigenous Populations During COVID-19 Through Community Partnerships

Speaker: Pam Ford, Omega Nurses – Specialty Health Clinic, Canada

Engaging The Disengaged: HCV Self Testing and Linkage to Care for Drug Treatment Service Users During COVID

Speaker: Louise Hansford, Inclusion, UK

Utilization of HCV Outreach Coordinator and Virtual HCV Care by Physician in an Opioid Substitution Clinic and Overdose Prevention Site to Enhance HCV Testing and Linkage to Care in Priority Populations During COVID Pandemic

Speaker: Elisa Venier, AMS/CATC Toronto, ON, Canada

Combined COVID-19 Vaccination and Hepatitis C Virus and HIV Screening Intervention For High-Risk Populations at a Mobile Testing Unit in Madrid, Spain

Speaker: Andrea Mochales, ISGlobal, Spain

COVID-19 Pandemic as a Barrier For Hepatitis C (HCV) Elimination For People Who Use Drugs (PWUD) in Greece

Speaker: Pinelopi Antonakaki, GI-Liver Unit, 2nd Dpt of Internal Medicine, National and Kapodistrian University of Athens,Hippocratio General Hospital, Greece 

Combined COVID-19 Vaccination and Hepatitis C Virus Screening Intervention For High-Risk Populations at a Centre For Addiction Services in Barcelona, Spain

Speaker: Andrea Mochales, ISGlobal, Spain

Innovations for Continuum of Care for People who Inject Drugs During COVID-19 Lock Down

Speaker: Taib Abdulrahman Basheeib, Reachout Centre Trust, Kenya

Implementing Blood Borne Virus (BBV) Self-Testing by Dry Blood Spot Test During the COVID-19 Pandemic in Scotland

Speaker: Caitlin Park, NHS Grampian, UK

Responding to a BBV Outbreak in the Midst of a Global Pandemic

Speaker: Bronagh McBrien, Public Health Agency, UK

COVID-19 Vaccination at a Swedish Needle Exchange Program – A Means of Fighting The Pandemic

Speaker: Eva-lena Öfverström, Department Of Infectious Diseases, University Hospital Skåne, Malmö, Sweden

Hepatitis C Treatment Among People Prescribed Methadone Maintenance at a U.S. Opioid Treatment Program During COVID-19 via Telehealth and Simplified Care Pathway

Speaker: Lynn Taylor, CODAC, USA

Filling The Gap- DBST at Home as a Mitigation for Reduced Face to Face in Alcohol and Drug Recovery Services Contact During COVID

Speaker: Julie Craik, NHS Greater Glasgow and Clyde, UK

Successful Interventions for HCV in The Inner City in COVID World

Speaker: Brian Conway, Vancouver Infectious Diseases Centre, Canada

Evidence of Limited Access to Harm Reduction Services in England, Wales and Northern Ireland in 2020 as a Result of COVID-19 Restrictions

Speaker: Sara Croxford, UK Health Security Agency, UK

Vaccination for SARS-CoV-2 Among Those in Prison Care in Scotland According to Recent Opioid Agonist Therapy History

Speaker: Maxim Wilkinson, Public Health Scotland, UK

Time-Series Analysis of Presentations to Four Syringe Dispensing Machines and a Needle and Syringe Program During COVID-19 Lockdowns in Melbourne, Australia

Speaker: Daniel O’Keefe, Burnet Institute, Australia

Low Prevalence of SARS-CoV-2 Infections and Antibodies Among Clients and Staff Members of Homeless Services in Amsterdam Following The Second Wave of Infections in The Netherlands: Did The Dutch Policy Work?

Speaker: Ellen Generaal, Public Health Service Of Amsterdam, Netherlands

Changes in Substance Use and Risk Behaviours for Hepatitis C Infection Among People Experiencing Homelessness Who Inject Drugs in Northern Ireland During the COVID-19 Pandemic

Speaker: Christopher Nugent, Public Health Agency, Northern Ireland, UK

South Australian Response to Facilitate Isolation Requirements in Aboriginal Homeless Substance Dependent People

Speaker: Bronwyn Gordon, Drug and Alcohol Services South Australia, Australia

Call Back: Retrieval of Hepatitis C Diagnosed Patients Who Were Lost to Follow Up. A Study From The C-Free-South Project.

Speaker: Sandra Dröse, Department of Clinical research, Faculty of Health Sciences, University of Southern Denmark, Denmark

Use of a Web Based Dashboard to Identify and Engage With People With Hepatitis C Admitted to Hospital

Speaker: Tom Prior, NHS Greater Glasgow & Clyde, UK

Peer Delivered Hepatitis C Testing in a Community Pharmacy – Meeting the Needs of People Who Inject Drugs

Speaker: Danny Morris, The Hepatitis C Trust, UK

Peer-Led Community Based Integrated Infectious Disease Testing and Linkage to Care in Inclusion Health Populations in London, UK

Speaker: Julian Surey, Find&Treat, UCLH NHS Trust, UK

A Mixed Methods Evaluation of an Innovative Peer+Clinician Outreach HCV Model of Care for Unstably Housed Populations in London, UK, Using the Integrated HCV Candidacy Framework

Speaker: Binta Sultan, Ucl, UK

Using Telephone-Based Patient Navigation Services to Access Hepatitis C Care in New York City With a Public Health Approach

Speaker: Liz Tang, New York City Department Of Health And Mental Hygiene, USA

Drop-In Group Medical Appointments (DIGMAs) Can Improve Patient Engagement in Hepatitis C Treatment

Speaker: Jaclyn Bandell, Western Carolina University, USA

Self Test, What Works Best?

Speaker: Leon Wylie, NHS Lanarkshire, UK

A Novel Testing Modality to Address Barriers to Hepatitis C Testing and Treatment Among Aboriginal and Torres Strait Islander People in New South Wales, Australia: The NSW DBS Pilot Study

Speaker: Anna Conway, Kirby Institute, UNSW, Australia

Integrating Hepatitis C Testing and Treatment Into Multiple Community Healthcare Settings for Those Who Inject Drugs: Facilitators and Barriers

Speaker: Gabriele Vojt, Glasgow Caledonian University, UK

Integrating Hepatitis C Testing and Treatment Into Community Healthcare Settings for Those Who Inject Drugs: Formulating Recommendations

Speaker: Gabriele Vojt, Glasgow Caledonian University, UK

Hepatitis C Virus Testing Uptake Among Hospitalized People Who Inject Drugs: Opportunities to Enhance the HCV Care Continuum

Speaker: Maja Skaland, Norwegian University of Science and Technology, Norway

VEND-C. Evaluating Distribution of Rapid HCV-Antibody Self-Testing Kits via Needle/Syringe Vending Machines: A Protocol Paper

Speaker: Daniel O’Keefe, Burnet Institute, Australia

Using Social Media to Improve Follow-Up and Routine Checks on Newly Diagnosed Young People Living With HIV and Their Adherence to Antiretroviral Therapy in Nigeria

Speaker: Kayode Owoso, 360 Health Systems Diagnostics And Correction (360 HSDC), Nigeria

A Feasibility Study to Increase Chronic Hepatitis C Virus RNA Testing and Linkage to Care Among Clients Attending Homeless Services in Amsterdam, The Netherlands

Speaker: Ellen Generaal, Public Health Service Of Amsterdam, Netherlands

Supporting People Living With HIV to be Cured of Hepatitis C Through Telephone Patient Navigation Services From the New York City Health Department

Speaker: Liz Tang, New York City Department Of Health And Mental Hygiene, USA

Rapid Screening for Blood Borne Viruses Through a Hostel Outreach Programme

Speaker: Bronagh McBrien, Public Health Agency, UK

Cost and Cost-Effectiveness of Hepatitis C Virus Self-Testing in Four Settings

Speaker: Josephine Walker, University Of Bristol, UK

The Role of Point-Of-Care Hepatitis C RNA Testing at Prison Intake For Reducing Barriers to The Hepatitis C Care Cascade

Speaker: Lise Lafferty, UNSW Sydney, Australia

The Drug User in Health Care System: A Training Proposal to Improve Access and Adherence to Care (Linkage to Care)

Speaker: Marcija (Marzia) Borojevic, University of Applied Sciences and Arts of Southern Switzerland Department of Business Economics, Health and Social Care, Switzerland

‘We All Lost Our Steam” – Barriers to Pharmacy-Based Identification and Treatment of Hepatitis C in Victoria, British Columbia

Speaker: Marion Selfridge, Cool Aid Community Health Centre, Canada

Reaching Hard to Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C in High-Income Settings

Speaker: Nicolas Nagot, University of Montpellier, France

Engaging People Who Use Drugs in Tayside Into Care to Decrease Risk of Drug-Related Mortality and Improve Health Outcomes; The ‘Cocoon’ Service Evaluation Project

Speaker: Christian Sharkeys, NHS Tayside, UK

Hepatitis C Treatment Uptake Following Dried Blood Spot Testing For Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot

Speaker: Anna Conway, Kirby Institute, UNSW, Australia

Need For Decentralization and Task-Shifting of Hepatitis C (HCV) Services With a Non-Judgemental Approach for People who Inject Drugs: Results From a Global Values and Preferences Survey

Speaker: Jessica Hicks, World Hepatitis Alliance, UK

A Phone-Based Integrated Intervention for Smoking Cessation Among Smokers Living With Hepatitis C: A Pilot Study

Speaker: Ashley Coleman, Prisma Health, USA

Evaluation of the Impact of HIV Diagnosis on the Hepatitis C Virus Care Cascade and Risk Behaviours Among Persons Receiving Medication Treatment for Opioid Use Disorder

Speaker: Sandra Springer, Yale School Of Medicine, USA

Hepatitis C in People Who Use Drugs: Timeline From Screening to Cure

Speaker: Alexandra Aguiar, Ser+, Portuguese Association For Aids Challenge And Prevention, Portugal

Community Screening in Key Populations: An Integrated Intervention in Two Fast-Track Cities With Significant HIV and Hepatitis C Prevalence

Speaker: Ana Marques, Ser+, Portuguese Association For Aids Challenge And Prevention, Portugal

Hepatitis Delta Virus: A Silent Threat to People Who Inject Drugs

Speaker: Beatrice Zovich, Hepatitis B Foundation, USA

Opportunities to Prevent Hepatitis B Infection Among People Who Use or Inject Drugs

Speaker: Ryan Clary, Hep B United, USA

Unsafe Sexual Practice Prior to Incarceration, a High-Risk Factor of HBV and HIV Infection Among Prisoners In Blantyre, Malawi

Speaker: Isaac Shawa, University Of Malawi, Malawi

Epidemiology of HIV Infection Among People who Inject Drugs in England, Wales and Northern Ireland: Nearly 40 Years On

Speaker: Sara Croxford, UK Health Security Agency, UK

Hepatitis B and C Viral Co-Infections Among HIV-1 Infected Individuals in South Kerala, India

Speaker: Sabin Katpattil, Kerala University Of Health Sciences, India

Ethical Considerations and Responsibilities in the Planning and Implementation of a Study on Infectious Diseases Among People Experiencing Homelessness in Berlin, Germany

Speaker: Navina Sarma, Robert Koch Institute, Germany

“Antihbc(+) Only” as a Marker of Hepatitis B Virus Infection in Drug Users Under Substitution Treatment in Greece

Speaker: Olga Anagnostou, Greek Organization Against Drugs (okana), Greece

Knowledge and Attitude Regarding HBV Infection and Vaccine Among Hospital Patients

Speaker: Asmin Sha, Educare Institute of Health Sciences, India

Screening for Infectious Diseases in At-Risk Populations: Preliminary Data From an Emergency Shelter in Lisbon for Homeless People With Addictions

Speaker: Claudia Pereira, Ares Do Pinhal, Portugal

Contact Tracing to Curbing HIV Transmission by Assessing Sexual Partners, Spouses, and Children of Newly Diagnosed Patients in Nigeria.

Speaker: Kayode Owoso, 360 Health Systems Diagnostics And Correction (360 HSDC), Nigeria

Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative study informed by drug, set and setting

Speaker: Elin Holmén, Stockholm Centre For Dependency Disorders/Karolinska Institute, Sweden

Psychosocial Predictors of Drug Overdose Among People Who Inject Drugs

Speaker: Oluwaseun Falade-Nwulia, Johns Hopkins University School Of Medicine, USA

Increased Access to Naloxone Among People Who Inject Drugs or Received Opioid Agonist Treatment, Including Those Who Have Experienced Recent Non-Fatal Opioid-Related Overdose in Australia

Speaker: M-J Stowe, Kirby Institute, University Of New South Wales, Australia

The ‘In The Moment Pilot’. Evaluating Methods of In-Situ Data Collection During Episodes of Injecting Drug Use to Improve Opioid Overdose Response: A Protocol Paper

Speaker: Daniel O’Keefe, Burnet Institute, Australia

Feasibility and Acceptability of an Overdose Prevention Intervention Delivered by Community Pharmacists for Patients Prescribed Opioids from Chronic Non-Cancer Pain

Speaker: Fiona Mercer, University Of Stirling, UK

Regional Broad Scale Implementation of Take Home Naloxon in Sweden, 42 Months Follow Up – Small Group Manages Large Proportion of Opioid Overdoses

Speaker: Pernilla Isendahl, Department of Infectious Diseases, University Hospital Skåne, Malmö, Sweden

Innovations in Overdose Prevention: Using the Telephone to Save Lives

Speaker: Amanda Davila, Never Use Alone, USA

Establishing, Embedding, and Supporting Peer Naloxone Supply Across Scotland – A Scottish Drug Deaths Taskforce (DDTF) Funded Project

Speaker: Wez Steele, Scottish Drugs Forum, UK

A Mixed Methods Evaluation of Peer-to-Peer Naloxone Training and Supply in Glasgow, Scotland

Speaker: Mathew Smith, Glasgow Caledonian University, UK

Personal Experience and Awareness of Opioid Overdose Occurrence Among Peers and Willingness to Administer Naloxone in South Africa: Findings From a Three‑City Pilot Survey of Homeless People Who Use Drugs

Speaker: Michael Wilson, Advance Access & Delivery SA, South Africa

Co-Produced Intervention(s) Development for Reducing Drug-Related Deaths in Scotland: A Systems Approach

Speaker: Kathryn Skivington, University of Glasgow, UK

I’ve Changed My Attitude. I’m Not So Against It. Facilitators of Acceptance by Institutional Staff of Canada’s First Prison Overdose Prevention Site

Speaker: Lynne Leonard, University of Ottawa, Canada

Monitoring for Fentanyl and Novel Psychoactive Substances Within Supervised Injecting Facilities: Testing Three Different Approaches in Australia

Speaker: Suzanne Nielsen, Monash Addiction Research Centre, Monash University, Australia

Drug Checking in Australia: Desired Service Design Features Among a Sample of People Who Use Heroin

Speaker: Rachel Sutherland, National Drug and Alcohol Research Centre, Australia

A Realist Synthesis of How Drug Checking Services are Designed and Implemented for People Who Use Drugs.

Speaker: Danilo Falzon, University of Stirling, UK

The HOPE App

Speaker: Eve MacLeod, NHS Highland, UK

Co-Morbidity, Social Experiences, and Service Engagement Among 4,451 Drug-Related Deaths in Scotland 2009-2016: A Network Analysis of 230 Complex Health and Social Conditions

Speaker: Rosie Seaman, University of Glasgow, UK

Emergency Department Visits Due to a Suspected Overdose Following Distribution of Income Assistance Payments in British Columbia, Canada

Speaker: Laurence Campeau, Public Health Agency Of Canada, Canada

Perceived Access to Opioid Agonist Treatment in Prison and Post-Release Among Persons With a History of Injection Drug Use: A Qualitative Study

Speaker: Alison Marshall, The Kirby Institute, Australia

Prison and Drugs in Europe: Drug Use, Drug Related Problems and Available Interventions

Speaker: Linda Montanari, European Monitoring Centre for Drugs and Drug Addiction, Portugal

Incidence of Non-Fatal and Fatal Opioid Overdose Following Release From Prison Among Men Who Regularly Injected Drugs Pre-Imprisonment: A Prospective Cohort Study

Speaker: Michael Curtis, Burnet Institute, Australia

The National Prisons Hepatitis Education Program (HepPEd Program): An Evidence-Based Hepatitis C Education Program to Enhance Public Health Literacy in the Australian Prison Sector

Speaker: Yumi Sheehan, The Kirby Institute, UNSW Sydney, Australia

Identifying Barriers and Enablers to Opt-Out Hepatitis C Virus Screening in Provincial Prisons in Quebec, Canada: A Qualitative Study With Prison-Based Healthcare Professionals Using The Theoretical Domains Framework

Speaker: Guillaume Fontaine, Centre for Implementation Research, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada

Gendered Pathways Towards Drugs and Incarceration: Results From a Research in Three Female Prisons in Italy and Portugal

Speaker: Linda Montanari, European Monitoring Centre for Drugs and Drug Addiction, Portugal

Prison to Community Follow Me Model

Speaker: Sean Cox, Hepatitis C Trust, UK

Metzineres. Environments of Shelter for Women Who Use Drugs Surviving Violence

Speaker: Aura Roig Forteza, Metzineres, Spain

“We Come to You”: Co-Locating Counselling With Kirketon Road Centre (KRC) South – A Primary Needle and Syringe Program (NSP) in Sydney’s Southern Region

Speaker: Julie Dubuc, Kirketon Road Centre, Australia

The Harm Reduction Model as a Tool to Enhance Health Care for People who use Drugs (PUD): The Experience of an Outreach Team Working With People who Experience Homelessness (PWEH)

Speaker: Teresa Castro, Ser+, Portuguese Association For Aids Challenge And Prevention, Portugal

Why Case Management is Not Sufficient Anymore… We Need Care Management

Speaker: Tessa Windelinckx, Vzw Free Clinic, Belgium

Improving Access to Addiction Medical Services for Homeless Indigenous Peoples in Montreal: An Integrated Care Model Across a Community-Based Managed Alcohol Program and Hospital-Based Addiction Services

Speaker: Stephanie Marsan, Centre Hospitalier De L’université De Montréal, Canada

Leveraging Public-Private-Community Partnership to Reduce Health Disparities Among People Who Use Drugs

Speaker: Amy Jessop, HepTREC at Prevention Point Philadelphia, USA

Indigenous Peer Mentorship Model of Care

Speaker: Cara Spence, University of Saskatchewan, Canada

Impact of State HIV and Hepatitis C (HCV) Screening Policies on HIV/HCV Testing Provision at Substance Use Disorder (SUD) Treatment Programs in The United States

Speaker: Czarina Behrends, Weill Cornell Medical College, USA

Development of a Measurement Instrument to Assess The Stigma Affecting People Who Use Drugs in The Western Cape

Speaker: Chanceline Kwakep Semegni, University Of Western Cape, South Africa

Worth The Cure: The Role of Community Engagement and Community-Led Reporting in National Hepatitis Efforts

Speaker: Sara Helena Pereira e Silva Gaspar, Treatment Action Group, Brazil

Impact of HCV Testing and Treatment Services On HCV Transmission Among Men who Have Sex With Men and Inject Drugs in San Francisco: a Modelling Analysis

Speaker: Adelina Artenie, University of Bristol, UK

Higher Incidence of HCV Re-Infection Among Treatment Experienced People who Inject Drugs in Tayside, Scotland

Speaker: Christopher Byrne, University of Dundee, UK

Modelling The Impact of The Care Cascade Amongst Young People Who Inject Drugs in San Francisco

Speaker: Hannah Fraser, University of Bristol, UK

The Hepatitis Engagement Program (HEP): Towards The Elimination of Hepatitis C Vertical Transmission in New Brunswick, Canada

Speaker: Kate Harland, Centre For Research, Education, And Clinical Care Of At-risk Populations, Canada

Reducing the Time-to-Treatment for Patients with HCV in English Remand Prisons

Speaker: Arran Ludlow Rhodes, Practice Plus Group, UK

Development and Validation of a Global Model to Optimize HIV Resource Allocation Among People Who Inject Drugs: The Intrepid Model

Speaker: Natasha Martin, University of University Of California San Diego, USA

Geographic Clustering of Social Injection Activity and Risk of Hepatitis C Virus Acquisition Among People Who Inject Drugs in Montreal

Speaker: Nanor Minoyan, CRCHUM / Université de Montréal, Canada

Phylogenetic Transmission Clusters of Hepatitis C Virus Among People Who Use Drugs Who Access Harm Reduction Services in Three South African Cities, 2016 – 2017

Speaker: Nkosenhle Ndlovu, National Institute for Communicable Diseases, South Africa

The Benefits of a Regional Collaborative Drug Related Death Review and Surveillance System: Insights From Implementation in the North West of England

Speaker: Howard Reed, Public Health Institute, Liverpool John Moores University, UK

Drug Dependence and Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy Among People with a Hepatitis C Notification in New South Wales, Australia

Speaker: Muhammad Yousafzai, The Kirby Institute, UNSW Sydney, Australia

Evaluation of Universal Hepatitis C Screening and Treatment among Psychiatry Inpatients

Speaker: Camelia Capraru, Toronto Centre For Liver Disease/viral Hepatitis Care Network (vircan), Canada

Rapid Hepatitis C Treatment Initiation in Young People who Inject Drugs: Final Results From The HCV-Seek, Test & Rapid Treatment (HCV-ST&RT) Randomized Pilot Clinical Trial

Speaker: Benjamin Eckhardt, NYU School of Medicine/Bellevue Hospital, USA

Dry Blood Spot Polymerase Chain Reaction (DBS PCR) Blood Borne Virus (BBV) Testing in The Setting of Police Custody

Speaker: Erica Peters, NHS Greater Glasgow And Clyde, UK

Evaluation of a Naloxone Pilot Among Police Officers in Scotland: A Public Health Approach to Policing

Speaker: Elizabeth Speakman, University of Dundee, UK

Integrated Medically Assisted Therapy Clinic for People Who Use Drugs, a Case of Karuri Clinic, Kiambu County, Kenya

Speaker: Angela Thiongo, Medecins Sans Frontieres (MSF), Kenya

Overlapping Adverse Health Outcomes Among People who Inject Drugs in England, Wales and Northern Ireland, 2019-2020

Speaker: Claire Edmundson, Civil Service, UK

Piloting a Digital Health Respiratory Monitoring Intervention to Reduce Drug-Related Deaths – The ‘RESCU’ Project

Speaker: Kristina Hnízdilová, University of Dundee, UK

A Systematic Review of Psychosocial Factors Associated With Risk of Drug-Related Overdose

Speaker: Amy Malaguti, NHS Tayside / University of Dundee, UK

The impact of COVID-19 in the consumption patterns of people who inject drugs

Speaker: Joana Pires, Médicos Do Mundo, Portugal

Promoting Community Naloxone Provision; Utilising People With Lived Experience to Address Drug Related Deaths Within Dundee

Speaker: Toni-Marie Porter, Hillcrest Futures, UK